title: Rationale and methods of the cardiometabolic Valencian study (Escarval-Risk) for validation of risk scales in Mediterranean patients with hypertension, diabetes or dyslipidemia.
abstract: BACKGROUND
  The Escarval-Risk study aims to validate cardiovascular risk scales in patients with hypertension, diabetes or dyslipidemia living in the Valencia Community, a European Mediterranean region, based on data from an electronic health recording system comparing predicted events with observed during 5 years follow-up study.
  
  
  METHODS
  A cohort prospective 5 years follow-up study has been designed including 25000 patients with hypertension, diabetes and/or dyslipidemia attended in usual clinical practice. All information is registered in a unique electronic health recording system (ABUCASIS) that is the usual way to register clinical practice in the Valencian Health System (primary and secondary care). The system covers about 95% of population (near 5 million people). The system is linked with database of mortality register, hospital withdrawals, prescriptions and assurance databases in which each individual have a unique identification number. Diagnoses in clinical practice are always registered based on IDC-9. Occurrence of CV disease was the main outcomes of interest. Risk survival analysis methods will be applied to estimate the cumulative incidence of developing CV events over time.
  
  
  CONCLUSIONS
  The Escarval-Risk study will provide information to validate different cardiovascular risk scales in patients with hypertension, diabetes or dyslipidemia from a low risk Mediterranean Region, the Valencia Community.
authors.affiliation: University Miguel Hernandez, Department of Clinical Medicine, San Juan de Alicante, Spain.
authors.forename: Vicente
authors.initials: V
authors.lastname: Gil-Guillen
authors.forename: Domingo
authors.initials: D
authors.lastname: Orozco-Beltran
authors.forename: Josep
authors.initials: J
authors.lastname: Redon
authors.forename: Salvador
authors.initials: S
authors.lastname: Pita-Fernandez
authors.forename: Jorge
authors.initials: J
authors.lastname: Navarro-Pérez
authors.forename: Vicente
authors.initials: V
authors.lastname: Pallares
authors.forename: Francisco
authors.initials: F
authors.lastname: Valls
authors.forename: Carlos
authors.initials: C
authors.lastname: Fluixa
authors.forename: Antonio
authors.initials: A
authors.lastname: Fernandez
authors.forename: Jose M
authors.initials: JM
authors.lastname: Martin-Moreno
authors.forename: Manuel
authors.initials: M
authors.lastname: Pascual-de-la-Torre
authors.forename: Jose L
authors.initials: JL
authors.lastname: Trillo
authors.forename: Ramon
authors.initials: R
authors.lastname: Durazo-Arvizu
authors.forename: Richard
authors.initials: R
authors.lastname: Cooper
authors.forename: Marta
authors.initials: M
authors.lastname: Hermenegildo
authors.forename: Luis
authors.initials: L
authors.lastname: Rosado
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002318:Cardiovascular Diseases / Q000453:epidemiology*; D015331:Cohort Studies; D003920:Diabetes Mellitus / Q000453:epidemiology*; D050171:Dyslipidemias / Q000453:epidemiology*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000453:epidemiology*; D008297:Male; D019083:Mediterranean Region; D008875:Middle Aged; D011446:Prospective Studies; D018570:Risk Assessment / Q000379:methods*